
Asia Pacific Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Meropenem, Doripenem, Imipenem, Tebipenem, and Others), Indication (Bacterial Meningitis, Acute Pelvic Infections, Respiratory Tract Infecti
Description
Asia Pacific Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Meropenem, Doripenem, Imipenem, Tebipenem, and Others), Indication (Bacterial Meningitis, Acute Pelvic Infections, Respiratory Tract Infections, Intra-Abdominal Infections, Urinary Tract Infections, and Others), and Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies)
The Asia Pacific carbapenem-based antibiotics market is expected to reach US$ 1,506.07 million by 2028 from US$ 1,072.76 million in 2021; it is estimated to grow at a CAGR of 5.0% from 2021 to 2028.
The market's growth is attributed to factors such as the rising prevalence of bacterial infections and increasing private and public partnerships of leading pharmaceutical players. However, the tedious and expensive process of developing antibiotics is expected to restrain the market's growth during the forecast period.
Generic versions are popular due to their availability and affordability. In addition, the expiry of patented carbapenem-based antibiotics has widen-up opportunities for generic drug manufacturers to enter the market with their cost-efficient drugs. The main focus of generic drug producers is to increase the reach of these drugs. Moreover, the shortage of antibiotics to treat bacterial infections is also one of the prime factors driving the market. The increased production of generic carbapenem-based antibiotics has increased drug availability in various low- and middle-income countries.
Generic versions of carbapenem drugs available in the market are ertapenem (Invanz), imipenem/cilastatin (Primaxin IM), doripenem (Doribax), and meropenem (Merrem). In addition, the growing number of generic players in the market is accelerating the production of generic drugs. Many Asian companies are engaged in developing active pharmaceutical ingredients (API), which are required to produce generic carbapenem-based antibiotics. In June 2021, JW Pharmaceutical, a South Korean company, announced it had completed production of its API for Ertapenem injection and shipped it to the US. The company plans to enter the global carbapenem antibiotic market in the coming years. It has also succeeded in developing its technology independently in Korea to produce Doripenem. Furthermore, the company plans to expand the sales of both API and finished drugs of Imipenem and Meropenem by exporting them to over 40 countries, including China and Japan. Therefore, accelerated generic drug production by the companies is driving the global carbapenem-based antibiotics market.
Asia Pacific Carbapenem-Based Antibiotics Market Revenue and Forecast to 2028 (US$ million)
ASIA PACIFIC CARBAPENEM-BASED ANTIBIOTICS MARKET SEGMENTATION
By Type
Meropenem Imipenem Doripenem Tebipenem Others By Indication
Bacterial Meningitis Acute Pelvic Infections Respiratory Tract Infections Intra-Abdominal Infections Urinary Tract Infections Others By Distribution Channel
Hospital Pharmacies Retail Pharmacies Online Pharmacies By Country
China India Japan South Korea Australia Rest of Asia Pacific Company Profiles
ACS Dobfar S.p.A Aurobindo Pharma Ltd DAEWOONG PHARMACEUTICAL CO., LTD Gland Pharma Limited Merck & Co., Inc. Sumitomo Dainippon Pharma Co., Ltd. Savior Lifetec Pfizer Inc. Spero Therapeutic
Reasons to Buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Paciifc carbapenem-based antibiotics market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Asia Paciifc carbapenem-based antibiotics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
The Asia Pacific carbapenem-based antibiotics market is expected to reach US$ 1,506.07 million by 2028 from US$ 1,072.76 million in 2021; it is estimated to grow at a CAGR of 5.0% from 2021 to 2028.
The market's growth is attributed to factors such as the rising prevalence of bacterial infections and increasing private and public partnerships of leading pharmaceutical players. However, the tedious and expensive process of developing antibiotics is expected to restrain the market's growth during the forecast period.
Generic versions are popular due to their availability and affordability. In addition, the expiry of patented carbapenem-based antibiotics has widen-up opportunities for generic drug manufacturers to enter the market with their cost-efficient drugs. The main focus of generic drug producers is to increase the reach of these drugs. Moreover, the shortage of antibiotics to treat bacterial infections is also one of the prime factors driving the market. The increased production of generic carbapenem-based antibiotics has increased drug availability in various low- and middle-income countries.
Generic versions of carbapenem drugs available in the market are ertapenem (Invanz), imipenem/cilastatin (Primaxin IM), doripenem (Doribax), and meropenem (Merrem). In addition, the growing number of generic players in the market is accelerating the production of generic drugs. Many Asian companies are engaged in developing active pharmaceutical ingredients (API), which are required to produce generic carbapenem-based antibiotics. In June 2021, JW Pharmaceutical, a South Korean company, announced it had completed production of its API for Ertapenem injection and shipped it to the US. The company plans to enter the global carbapenem antibiotic market in the coming years. It has also succeeded in developing its technology independently in Korea to produce Doripenem. Furthermore, the company plans to expand the sales of both API and finished drugs of Imipenem and Meropenem by exporting them to over 40 countries, including China and Japan. Therefore, accelerated generic drug production by the companies is driving the global carbapenem-based antibiotics market.
Asia Pacific Carbapenem-Based Antibiotics Market Revenue and Forecast to 2028 (US$ million)
ASIA PACIFIC CARBAPENEM-BASED ANTIBIOTICS MARKET SEGMENTATION
By Type
Meropenem Imipenem Doripenem Tebipenem Others By Indication
Bacterial Meningitis Acute Pelvic Infections Respiratory Tract Infections Intra-Abdominal Infections Urinary Tract Infections Others By Distribution Channel
Hospital Pharmacies Retail Pharmacies Online Pharmacies By Country
China India Japan South Korea Australia Rest of Asia Pacific Company Profiles
ACS Dobfar S.p.A Aurobindo Pharma Ltd DAEWOONG PHARMACEUTICAL CO., LTD Gland Pharma Limited Merck & Co., Inc. Sumitomo Dainippon Pharma Co., Ltd. Savior Lifetec Pfizer Inc. Spero Therapeutic
Reasons to Buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Paciifc carbapenem-based antibiotics market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Asia Paciifc carbapenem-based antibiotics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table of Contents
152 Pages
- 1. Introduction
- 1.1 Scope of the Study
- 1.2 The Insight Partners Research Report Guidance
- 1.3 Market Segmentation
- 1.3.1 Asia Pacific Carbapenem-based Antibiotics Market - By Type
- 1.3.2 Asia Pacific Carbapenem-based Antibiotics Market - By Indication
- 1.3.3 Asia Pacific Carbapenem-based Antibiotics Market - By Distribution Channel
- 1.3.4 Asia Pacific Carbapenem-based Antibiotics Market - By Country
- 2. Carbapenem-based Antibiotics Market - Key Takeaways
- 3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
- 4. Asia Pacific Carbapenem-based Antibiotics Market - Market Landscape
- 4.1 Overview
- 4.2 PEST Analysis
- 4.2.1 Asia Pacific- PEST Analysis
- 4.3 Expert Opinions
- 5. Carbapenem-based Antibiotics Market - Key Market Dynamics
- 5.1 Drivers
- 5.1.1 Rising Prevalence of Gram-Negative Bacterial Infections
- 5.1.2 Increasing Production of Generic Drugs
- 5.2 Market Restraints
- 5.2.1 Tedious and Expensive Process of Antibiotic Development
- 5.3 Market Opportunities
- 5.3.1 Private and Public Partnerships
- 5.4 Future Trends
- 5.4.1 Strategic Advancement for New Antibiotic Identification
- 5.5 Impact Analysis
- 6. Carbapenem-based Antibiotics Market -Asia Pacific Analysis
- 6.1 Asia Pacific Carbapenem-based Antibiotics Market Revenue Forecast and Analysis
- 7. Carbapenem-based Antibiotics Market Analysis - By Type
- 7.1 Overview
- 7.2 Carbapenem-based Antibiotics Market Revenue Share, by Type (2021 and 2028)
- 7.3 Meropenem
- 7.3.1 Overview
- 7.3.2 Meropenem: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- 7.4 Doripenem
- 7.4.1 Overview
- 7.4.2 Doripenem: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- 7.5 Imipenem
- 7.5.1 Overview
- 7.5.2 Imipenem: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- 7.6 Tebipenem
- 7.6.1 Overview
- 7.6.2 Tebipenem: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- 7.7 Others
- 7.7.1 Overview
- 7.7.2 Others: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- 8. Carbapenem-based Antibiotics Market - By Indication
- 8.1 Overview
- 8.2 Carbapenem-based Antibiotics Market, by Indication, 2021 and 2028 (%)
- 8.3 Bacterial Meningitis
- 8.3.1 Overview
- 8.3.2 Bacterial Meningitis: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.4 Acute Pelvic Infections
- 8.4.1 Overview
- 8.4.2 Acute Pelvic Infections: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.5 Respiratory Tract Infections
- 8.5.1 Overview
- 8.5.2 Respiratory Tract Infections: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.6 Intra-abdominal Infections
- 8.6.1 Overview
- 8.6.2 Intra-abdominal Infections: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.7 Urinary Tract Infections
- 8.7.1 Overview
- 8.7.2 Urinary Tract Infections: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.8 Others
- 8.8.1 Overview
- 8.8.2 Others: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- 9. Carbapenem-based Antibiotics Market - By Distribution Channel
- 9.1 Overview
- 9.2 Carbapenem-based Antibiotics Market, by Distribution Channel, 2021 and 2028 (%)
- 9.3 Retail Pharmacies
- 9.3.1 Overview
- 9.3.2 Retail Pharmacies: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- 9.4 Online Pharmacies
- 9.4.1 Overview
- 9.4.2 Online Pharmacies: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- 9.5 Hospital Pharmacies
- 9.5.1 Overview
- 9.5.2 Hospital Pharmacies: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- 10. Asia Pacific Carbapenem-based Antibiotics Market -Country Analysis
- 10.1 Asia Pacific: Carbapenem-based Antibiotics Market
- 10.1.1 Overview
- 10.1.2 Asia Pacific: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ ‘Million)
- 10.1.3 Asia Pacific: Carbapenem-based Antibiotics Market, by Type, 2019-2028 (US$ ‘Million)
- 10.1.4 Asia Pacific: Carbapenem-based Antibiotics Market, by Indication, 2019-2028 (US$ Million)
- 10.1.5 Asia Pacific: Carbapenem-based Antibiotics Market, by Distribution Channel, 2019-2028 (US$ Million)
- 10.1.6 Asia Pacific: Carbapenem-based Antibiotics Market, by Country, 2021 & 2028 (%)
- 10.1.6.1 China: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ ‘Million)
- 10.1.6.1.1 China: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ ‘Million)
- 10.1.6.1.2 China: Carbapenem-based Antibiotics Market, by Type, 2019-2028 (US$ ‘Million)
- 10.1.6.1.3 China: Carbapenem-based Antibiotics Market, by Indication, 2019-2028 (US$ ‘Million)
- 10.1.6.1.4 China: Carbapenem-based Antibiotics Market, by Distribution Channel, 2019-2028 (US$ ‘Million)
- 10.1.6.2 Japan: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ ‘Million)
- 10.1.6.2.1 Japan: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ ‘Million)
- 10.1.6.2.2 Japan: Carbapenem-based Antibiotics Market, by Type, 2019-2028 (US$ ‘Million)
- 10.1.6.2.3 Japan: Carbapenem-based Antibiotics Market, by Indication, 2019-2028 (US$ ‘Million)
- 10.1.6.2.4 Japan: Carbapenem-based Antibiotics Market, by Distribution Channel, 2019-2028 (US$ ‘Million)
- 10.1.6.3 India: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ ‘Million)
- 10.1.6.3.1 India: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ ‘Million)
- 10.1.6.3.2 India: Carbapenem-based Antibiotics Market, by Type, 2019-2028 (US$ ‘Million)
- 10.1.6.3.3 India: Carbapenem-based Antibiotics Market, by Indication, 2019-2028 (US$ ‘Million)
- 10.1.6.3.4 India: Carbapenem-based Antibiotics Market, by Distribution Channel, 2019-2028 (US$ ‘Million)
- 10.1.6.4 Australia: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ ‘Million)
- 10.1.6.4.1 Australia: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ ‘Million)
- 10.1.6.4.2 Australia: Carbapenem-based Antibiotics Market, by Type, 2019-2028 (US$ ‘Million)
- 10.1.6.4.3 Australia: Carbapenem-based Antibiotics Market, by Indication, 2019-2028 (US$ ‘Million)
- 10.1.6.4.4 Australia: Carbapenem-based Antibiotics Market, by Distribution Channel, 2019-2028 (US$ ‘Million)
- 10.1.6.5 South Korea: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ ‘Million)
- 10.1.6.5.1 South Korea: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ ‘Million)
- 10.1.6.5.2 South Korea: Carbapenem-based Antibiotics Market, by Type, 2019-2028 (US$ ‘Million)
- 10.1.6.5.3 South Korea: Carbapenem-based Antibiotics Market, by Indication, 2019-2028 (US$ ‘Million)
- 10.1.6.5.4 South Korea: Carbapenem-based Antibiotics Market, by Distribution Channel, 2019-2028 (US$ ‘Million)
- 10.1.6.6 Rest of Asia Pacific: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ ‘Million)
- 10.1.6.6.1 Rest of Asia Pacific: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ ‘Million)
- 10.1.6.6.2 Rest of Asia Pacific: Carbapenem-based Antibiotics Market, by Type, 2019-2028 (US$ ‘Million)
- 10.1.6.6.3 Rest of Asia Pacific: Carbapenem-based Antibiotics Market, by Indication, 2019-2028 (US$ ‘Million)
- 10.1.6.6.4 Rest of Asia Pacific: Carbapenem-based Antibiotics Market, by Distribution Channel, 2019-2028 (US$ ‘Million)
- 11. Impact of COVID-19 Pandemic on Asia Pacific Carbapenem-based Antibiotics Market
- 11.1 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
- 12. Carbapenem-based Antibiotics Market-Industry Landscape
- 12.1 Overview
- 12.2 Organic Developments
- 12.2.1 Overview
- 12.3 Inorganic Developments
- 12.3.1 Overview
- 13. COMPANY PROFILES
- 13.1 ACS Dobfar S.p.A
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
- 13.2 DAEWOONG PHARMACEUTICAL CO.,LTD
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
- 13.3 Aurobindo Pharma Ltd
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
- 13.4 Gland Pharma Limited
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
- 13.5 Merck & Co., Inc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
- 13.6 Sumitomo Dainippon Pharma Co., Ltd.
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
- 13.7 Savior Lifetec
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
- 13.8 Pfizer Inc.
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
- 13.9 Spero Therapeutics
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
- 14. Appendix
- 14.1 About The Insight Partners
- 14.2 Glossary of Terms
- List of Tables
- Table 1. Asia Pacific: Carbapenem-based Antibiotics Market, by Type - Revenue and Forecast to 2028 (US$ ‘Million)
- Table 2. Asia Pacific: Carbapenem-based Antibiotics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
- Table 3. Asia Pacific: Carbapenem-based Antibiotics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
- Table 4. China: Carbapenem-based Antibiotics Market, by Type - Revenue and Forecast to 2028 (US$ ‘Million)
- Table 5. China: Carbapenem-based Antibiotics Market, by Indication - Revenue and Forecast to 2028 (US$ ‘Million)
- Table 6. China: Carbapenem-based Antibiotics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ ‘Million)
- Table 7. Japan: Carbapenem-based Antibiotics Market, by Type - Revenue and Forecast to 2028 (US$ ‘Million)
- Table 8. Japan: Carbapenem-based Antibiotics Market, by Indication - Revenue and Forecast to 2028 (US$ ‘Million)
- Table 9. Japan: Carbapenem-based Antibiotics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ ‘Million)
- Table 10. India: Carbapenem-based Antibiotics Market, by Type - Revenue and Forecast to 2028 (US$ ‘Million)
- Table 11. India: Carbapenem-based Antibiotics Market, by Indication - Revenue and Forecast to 2028 (US$ ‘Million)
- Table 12. India: Carbapenem-based Antibiotics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ ‘Million)
- Table 13. Australia: Carbapenem-based Antibiotics Market, by Type - Revenue and Forecast to 2028 (US$ ‘Million)
- Table 14. Australia: Carbapenem-based Antibiotics Market, by Indication - Revenue and Forecast to 2028 (US$ ‘Million)
- Table 15. Australia: Carbapenem-based Antibiotics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ ‘Million)
- Table 16. South Korea: Carbapenem-based Antibiotics Market, by Type - Revenue and Forecast to 2028 (US$ ‘Million)
- Table 17. South Korea: Carbapenem-based Antibiotics Market, by Indication - Revenue and Forecast to 2028 (US$ ‘Million)
- Table 18. South Korea: Carbapenem-based Antibiotics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ ‘Million)
- Table 19. Rest of Asia Pacific: Carbapenem-based Antibiotics Market, by Type - Revenue and Forecast to 2028 (US$ ‘Million)
- Table 20. Rest of Asia Pacific: Carbapenem-based Antibiotics Market, by Indication - Revenue and Forecast to 2028 (US$ ‘Million)
- Table 21. Rest of Asia Pacific: Carbapenem-based Antibiotics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ ‘Million)
- Table 22. Organic Developments in the Carbapenem-based Antibiotics Market
- Table 23. Inorganic Developments in the Carbapenem-based Antibiotics Market
- Table 24. Glossary of Terms, Carbapenem-based Antibiotics Market
- List of Figures
- Figure 1. Carbapenem-based Antibiotics Market Segmentation
- Figure 2. Carbapenem-based Antibiotics Segmentation, By Country
- Figure 3. Asia Pacific Carbapenem-based Antibiotics Market Overview
- Figure 4. The Others Segment Held Largest Share of Type Segment in Carbapenem-based Antibiotics Market
- Figure 5. Asia Pacific Carbapenem-based Antibiotics Market- Leading Country Markets (US$ Million)
- Figure 6. Asia Pacific PEST Analysis
- Figure 7. Carbapenem-based Antibiotics Market Impact Analysis of Driver and Restraints
- Figure 8. Asia Pacific Carbapenem-based Antibiotics Market - Revenue Forecast and Analysis - 2021- 2028
- Figure 9. Carbapenem-based Antibiotics Market Revenue Share, by Type (2021 and 2028)
- Figure 10. Meropenem: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 11. Doripenem: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 12. Imipenem: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 13. Tebipenem: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 14. Others: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 15. Carbapenem-based Antibiotics Market, by Indication, 2021 and 2028 (%)
- Figure 16. Bacterial Meningitis: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 17. Acute Pelvic Infections: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 18. Respiratory Tract Infections: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 19. Intra-abdominal Infections: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 20. Urinary Tract Infections: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 21. Others: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 22. Carbapenem-based Antibiotics Market, by Distribution Channel, 2021 and 2028 (%)
- Figure 23. Retail Pharmacies: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 24. Online Pharmacies: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 25. Hospital Pharmacies: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 26. Asia Pacific: Carbapenem-based Antibiotics Market, by Key Country - Revenue (2021) (US$ ‘Million)
- Figure 27. Asia Pacific: Carbapenem-based Antibiotics Market Revenue and Forecast to 2028 (US$ ‘Million)
- Figure 28. Asia Pacific: Carbapenem-based Antibiotics Market, by Country, 2021 & 2028 (%)
- Figure 29. China: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ ‘Million)
- Figure 30. Japan: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ ‘Million)
- Figure 31. India: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ ‘Million)
- Figure 32. Australia: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ ‘Million)
- Figure 33. South Korea: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ ‘Million)
- Figure 34. Rest of Asia Pacific: Carbapenem-based Antibiotics Market - Revenue and Forecast to 2028 (US$ ‘Million)
- Figure 35. Impact Of COVID-19 Pandemic in Asia-Pacific Country Markets
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.